Molecular Imaging of Retrograde Nerve Transport

逆行神经运输的分子成像

基本信息

批准号：
8231332
负责人：
Dawid none Schellingerhout
金额：
$ 34.56万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-03-01 至 2015-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8231332
关键词：
Ablation Affect Alcohols Amputation Amyotrophic Lateral Sclerosis Anatomic Sites Anatomy Angiography Animal Model Animals Axonal Transport Back Basic Science Blindness Blood Vessels Brain Cancer Center Caring Clinical Clinical Research Colorectal Cancer Contrast Media Cranial Nerves Crush Injury Data Diabetes Mellitus Diabetic Neuropathies Diagnosis Diagnostic Discipline of Nuclear Medicine Disease Dose Dose-Limiting Early Diagnosis Effectiveness Erectile dysfunction Face Facial paralysis Failure Goals Gray unit of radiation dose Head and neck structure Human Image Imagery Imaging technology Injury Label Lead Learning Leg Methodology Modeling Monitor Mus Neck Nerve Nerve Growth Factors Nerve Tissue Nerve compression syndrome Neuronal Plasticity Neurons Neuropathy New Agents Numbness Operative Surgical Procedures Optics Outcome Paralysed Patient Care Patients Peptides Peripheral Nerves Peripheral Nervous System Diseases Physiological Population Positron-Emission Tomography Prevention Process Radiation Radiation Injuries Recurrent Laryngeal Nerve Research Resources Slipped Disk Spinal cord injury Surgical Models System Technology Testing Therapeutic Time Tracer Translational Research Translations Trauma Traumatic Nerve Injury Variant Vertebral column Vocal Cord Paralysis Voice Work base burden of illness chemotherapy clinical care clinically relevant deafness diabetic experience fast axonal transport foot imaging modality imaging probe improved in vivo innovation insight molecular imaging multimodality neoplastic nerve injury neurotoxic optic nerve disorder oxaliplatin prevent programs prostate surgery public health relevance research and development retrograde transport skills tetanus toxin fragment C

项目摘要

DESCRIPTION (provided by applicant): We seek to develop an imaging agent for Neurography, to allow nerves to be rendered visible to imaging. Our imaging agent will be analogous to Angiographic contrast agents used to make blood vessels visible to imaging, but applied to nerves. This will allow us to show both the anatomy and function of nerves, something that is currently very difficult to do, and will improve the preventative, diagnostic and therapeutic options we can offer to patients with nerve diseases. There are many nerve diseases that could benefit from improved imaging, too many to list but including: Preventing damage to the nerve bundles leading to erectile dysfunction after prostate surgery. Preventing loss of voice after neck surgery due to recurrent laryngeal nerve damage. Correctly diagnosing pinched nerves due to herniated disks in the spine. Diagnosing nerve disease leading to loss of sensation in the feet due to diabetes earlier, and monitoring treatments for this neuropathy to see if it is working effectively. Improving diagnosis and treatment in paralysis due to nerve trauma or spinal cord injury. Blindness, deafness and many other nerve diseases could be diagnosed better, treated better or perhaps even prevented from happening in the first place if we had improved nerve imaging. We see nerve imaging (Neurography) as a platform technology that could improve the day-to-day clinical care of patients with nerve disease; and also have a high impact on clinical, basic and translational research in the field. We have already shown that we can do Neurography with a fluorescently labeled agent within the sciatic (leg) nerves of mice and that we can use this to show the effects of a toxic chemotherapeutic in common use (oxaliplatin) on nerve transport. In this application we hope to: 1-extend our experience to other anatomic sites, specifically the cranial nerves where crippling nerve disease frequently occurs, 2-develop new variants of our agent to improve our imaging abilities with nuclear medicine scanners, and add imaging capabilities with bio- luminescent and positron emission tomography imaging, and 3-determine the effectiveness and utility of our agents in animal models of common nerve diseases like traumatic, toxic or radiation injury to the nerves. The information we learn from this project will show us how to move this imaging agent forward for use in patients. PUBLIC HEALTH RELEVANCE: Nerve diseases cause a great deal of harm, ranging from blindness, to paralysis to amputations on diabetics because of neuropathy. Despite this burden of disease, we have no imaging contrast agents to effectively image nerves. We propose to develop an agent for Neurography, analogous to Angiography.

描述（由申请人提供）：我们寻求开发一种用于神经造影的成像剂，以使神经在成像中可见。我们的显像剂类似于血管造影造影剂，用于使血管成像可见，但应用于神经。这将使我们能够展示神经的解剖结构和功能，这是目前很难做到的，并将改善我们为神经疾病患者提供的预防、诊断和治疗选择。有许多神经疾病可以从改善成像中受益，数量太多，无法一一列举，但包括：防止神经束损伤，导致前列腺手术后勃起功能障碍。防止颈部手术后因喉返神经损伤而失声。正确诊断由于脊柱椎间盘突出导致的神经受压。尽早诊断出因糖尿病而导致足部感觉丧失的神经疾病，并监测这种神经病变的治疗方法，看看其是否有效。改善神经创伤或脊髓损伤所致瘫痪的诊断和治疗。如果我们改进了神经成像技术，失明、耳聋和许多其他神经疾病就可以得到更好的诊断、更好的治疗，甚至可能从一开始就被预防。我们将神经成像（神经造影）视为一种平台技术，可以改善神经疾病患者的日常临床护理；并对该领域的临床、基础和转化研究也产生了很大影响。我们已经证明，我们可以在小鼠坐骨（腿）神经内使用荧光标记试剂进行神经造影，并且我们可以用它来显示常用的有毒化疗药物（奥沙利铂）对神经运输的影响。在此应用中，我们希望：1-将我们的经验扩展到其他解剖部位，特别是经常发生致残性神经疾病的脑神经，2-开发我们的药剂的新变体，以提高我们使用核医学扫描仪的成像能力，并增加成像功能通过生物发光和正电子发射断层扫描成像，以及 3-确定我们的药物在常见神经疾病（如神经创伤、中毒或辐射损伤）动物模型中的有效性和实用性。我们从这个项目中学到的信息将向我们展示如何推动这种显像剂用于患者。公共健康相关性：神经疾病会造成很大的伤害，从失明、瘫痪到糖尿病患者因神经病而截肢。尽管存在这种疾病负担，但我们没有成像造影剂来有效地对神经进行成像。我们建议开发一种神经造影剂，类似于血管造影剂。